RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?

Auteur(s) / Author(s)

WAGENBLAST Jens (1) ; BAGHI Mehran (1) ; MÖRTEL Susanne (1) ; HIRTH Daniel (1) ; THRON Laura (1) ; ARNOLDNER Christoph (2) ; GSTÖTTNER Wolfgang (2) ; MAY Angelika (1) ; HAMBEK Markus (1) ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) ENT Department, Goethe University Medical School, Frankfurt am Main, ALLEMAGNE
(2) ENT Department, Medical University of Vienna, AUTRICHE

Résumé / Abstract

Glucocorticoids such as dexamethasone are widely used as comedication in the treatment of head and neck cancer, e.g., to improve appetite and decrease weight loss and fatigue in patients with advanced disease or as antiallergic and antiemetic prophylaxis during anti-EGFR therapy. However, the literature suggests that dexamethasone induces resistance to antineoplastic agents in many solid tumor models in vitro and in vivo. Since this phenomenon has never been investigated in head and neck cancer, the present study was conducted to investigate the effect of dexamethasone on the antiproliferative activity of cetuximab in vitro in squamous cell carcinoma of the head and neck (SCCHN) cell lines. The antiproliferative effect of the anti-EGFR agent cetuximab alone and in combination with increasing concentrations of dexamethasone was examined in eight SCCHN cell lines at three different time-points (24, 48 and 72 h). Cell growth inhibition and viability were measured quantitatively using WST and LDH assays. Absolute tumor cell numbers were determined by cell counting in a Rosenthal chamber. Cetuximab alone inhibited the growth of all eight SCCHN cell lines significantly (p=0.008). In some cases the addition of dexamethasone reduced the antiproliferative activity of cetuximab (p≤0.038) but remained significant in all of the eight SCCHN cell lines compared with untreated controls (p≤0.028) at each drug concentration and each time-point. In contrast to the results reported for other tumor models, in our study dexamethasone showed in the majority of the evaluated dexamethasone drug concentrations and time-points no inhibition of the cytotoxic activity of cetuximab. The reasons for these discrepant findings are unclear but may be related to the degree of tumor cell differentiation or proliferation rate. Thus, further studies are required to elucidate the molecular mechanisms underlying the interaction between dexamethasone and cetuximab in different tumors.

Revue / Journal Title

Oncology reports    ISSN  1021-335X 

Source / Source

2009, vol. 22, no1, pp. 171-176 [6 page(s) (article)] (28 ref.)

Langue / Language

Anglais

Editeur / Publisher

Spandidos, Athens, GRECE  (1994) (Revue)

Mots-clés anglais / English Keywords

ENT disease

;

Skin disease

;

Cancer

;

Malignant tumor

;

Epidermal growth factor receptor

;

Monoclonal antibody

;

Steroid hormone

;

Corticosteroid

;

Cancerology

;

Cell death

;

Head and neck squamous cell carcinoma

;

Apoptosis

;

Resistance

;

Basal cell carcinoma

;

Head and neck cancer

;

Head and neck

;

Squamous cell carcinoma

;

Established cell line

;

Biological activity

;

Cetuximab

;

Antineoplastic agent

;

Inhibitor

;

Dexamethasone

;

Mots-clés français / French Keywords

Anti-EGFR

;

Pathologie ORL

;

Pathologie de la peau

;

Cancer

;

Tumeur maligne

;

Récepteur facteur croissance épiderme

;

Anticorps monoclonal

;

Hormone stéroïde

;

Corticostéroïde

;

Cancérologie

;

Mort cellulaire

;

Carcinome épidermoïde de la tête et du cou

;

Apoptose

;

Résistance

;

Carcinome basocellulaire

;

Cancer de la tête et du cou

;

Tête cou

;

Carcinome épidermoïde

;

Lignée cellulaire établie

;

Activité biologique

;

Cétuximab

;

Anticancéreux

;

Inhibiteur

;

Dexaméthasone

;

Mots-clés espagnols / Spanish Keywords

ORL patología

;

Piel patología

;

Cáncer

;

Tumor maligno

;

Receptor del factor de crecimiento epidérmico

;

Anticuerpo monoclonal

;

Hormona esteroide

;

Corticoesteroide

;

Cancerología

;

Muerte celular

;

Carcinoma epidermoideo cabeza cuello

;

Apoptosis

;

Resistencia

;

Carcinoma basocelular

;

Cáncer de cabeza y cuello

;

Cabeza cuello

;

Carcinoma epidermoide

;

Línea celular establecida

;

Actividad biológica

;

Cetuximab

;

Anticanceroso

;

Inhibidor

;

Dexametasona

;

Mots-clés d'auteur / Author Keywords

cetuximab

;

dexamethasone

;

squamous cell carcinoma of the head and neck cell lines

;

resistance

;

apoptosis

;

Localisation / Location

INIST-CNRS, Cote INIST : 26534, 35400018712456.0240

Nº notice refdoc (ud4) : 21649471



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas